Clinical Trial: Clostridium Butyricum CBM588(R) vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD)

U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852274) titled 'Clostridium Butyricum CBM588(R) vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD)' on Feb. 22.

Brief Summary: This randomized, real-life, single-center clinical trial aims to compare the efficacy and safety of probiotic Clostridium butyricum CBM588(R) (Butirrisan(R)) versus Rifaximin in the management of Symptomatic Uncomplicated Diverticular Disease (SUDD). Patients with diverticulosis and a history of mild-to-moderate diverticulitis will be randomized into two treatment groups:

Experimental Group: Clostridium butyricum CBM588(R) (Butirrisan(R)) + fiber supplementation Control Group: Rifaximin + fiber supplem...